FOR IMMEDIATE RELEASE West Chester, PA December 8, 2022, 6:01 am Eastern Standard Time (Business Wire)– Molecular Targeting Technologies,…

Read more MTTI obtains FDA allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer

FOR IMMEDIATE RELEASE West Chester, Pennsylvania, December 6, 2022 — Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of…

Read more MTTI Receives Chinese Patent for EVATHERA Technology

Molecular Targeting Technologies, Inc. (MTTI), announced that the first patient has been dosed in a clinical trial of EBTATE…

Read more MTTI doses first patient in EBTATE neuroendocrine tumor clinical trial

West Chester, PA, June 9, 2022 — Molecular Targeting Technologies, Inc. (MTTI), a clinical stage oncology company, will highlight…

Read more MTTI features EBTATE advances at the 2022 SNMMI meeting in Vancouver, BC

Molecular Targeting Technologies, Inc. Announces a new PET imaging agent for Rapid Monitoring Tumor Response to Therapy. Read more

Read more New PET imaging agent for Rapid Monitoring Tumor Response to Therapy

The Zhu Zhaohui/Chen Xiaoyuan team develops more effective, safer and more economical new radiotherapy drugs for neuroendocrine tumors Read…

Read more EBTATE is safe and effective in tumor control